Dataset from A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis, in Both Acute and Maintenance Phases
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/00007258
下载链接
链接失效反馈官方服务：
资源简介：
To assess clinical response to MMX mesalamine/mesalazine between a low and high dose in
children and adolescents aged 5-17 years with mild to moderate Ulcerative Colitis (UC) or who
are in remission.
创建时间：
2024-11-26
